Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

53.57 +2.32 (+4.53%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

28 29 30 31 32 33 34 35 Next >

'Halftime Report' Traders Share Their Thoughts On Crispr Therapeutics And Bed Bath & Beyond ↗

June 30, 2021

Amy Raskin said on CNBC's "Fast Money Halftime Report" that she would hold Crispr Therapeutics AG (NASDAQ: CRSP). She doesn't own the stock, but she owns...

Via Benzinga

Gene Editing Stocks: Why EDIT, CRSP, NTLA Stocks Continue to Soar ↗

June 30, 2021

Today, gene editing stocks are soaring amid increasingly bullish sentiment in this sector following strong results from Intellia.

Via InvestorPlace

Why Gene Editing Stocks Are Trading Higher Again Today ↗

June 30, 2021

Shares of gene editing stocks are continuing higher in sympathy with peer company Intellia (NASDAQ: NTLA), which gained in recent sessions following positive data for its...

Via Benzinga

44 Stocks Moving In Monday's Mid-Day Session ↗

June 28, 2021

Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy. Marin Software...

Via Benzinga

60 Biggest Movers From Yesterday ↗

June 29, 2021

Gainers Marin Software Incorporated (NASDAQ: MRIN) surged 96.9% to close at $7.50. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its...

Via Benzinga

Intellia Stock Leads Biotech Rally On Historic Moment For CRISPR ↗

June 28, 2021

Intellia led a rally for CRISPR stocks on Monday on early promise for its gene-editing drug. The news sent NTLA stock to a record high.

Via Investor's Business Daily

Gene Editing Stocks: The Big News Lifting EDIT, BNGO, CRSP and NTLA Stocks ↗

June 28, 2021

Gene editing stocks, led by NTLA stock, are powering higher on Monday following a landmark announcement by Intellia Therapeutics.

Via InvestorPlace

24 Stocks Moving in Monday's Pre-Market Session ↗

June 28, 2021

Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) rose 28.9% to $114.49 in pre-market trading. Intellia Therapeutics and Regeneron Pharmaceuticals disclosed positive interim...

Via Benzinga

Crispr Therapeutics Stock Sees Improved Relative Strength Rating ↗

June 25, 2021

Crispr Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 68 to 74.

Via Investor's Business Daily

Gold Stocks On Sale ↗

June 20, 2021

In this video, we discuss our top stocks of the week, how gold is on sale, and how some market signals have been particularly troubling and misread.

Via Talk Markets

Healthcare Portfolio Playbook: Time To Rebalance With MedTech ↗

June 18, 2021

As we look to re-balance our portfolio in the near-term, investors should consider adding Medtech as we have suggested in the past. Though, more recently, we have also focused on large-cap...

Via Talk Markets

Cramer Gives His Opinion On Bank of America, Advanced Micro Devices And More ↗

June 17, 2021

On CNBC's "Mad Money Lightning Round," Jim Cramer said Martin Marietta Materials, Inc. (NYSE: MLM) is a well-run company. He likes the stock because it doesn't...

Via Benzinga

CRISPR Therapeutics, Capsida Collaborate To Develop Gene-Edited Therapies For Neurological Diseases ↗

June 15, 2021

CRISPR Therapeutics (NASDAQ: CRSP) has signed a deal with Capsida Biotherapeutics, a gene therapy player specializing in AAV engineering, to carve out a...

Via Benzinga

Can Vertex Pharmaceuticals Recover From Its Latest Setback? ↗

June 15, 2021

Shares of the biotech industry leader have taken a big hit thanks to a clinical development pipeline that hasn't produced any big wins lately.

Via The Motley Fool

Is It Too Late to Buy Vertex Pharmaceuticals Stock? ↗

June 15, 2021

This biotech has likely reached its peak potential, for now.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2021 ↗

June 14, 2021

Upgrades Piper Sandler upgraded the previous rating for Boston Properties Inc (NYSE:BXP) from Neutral to Overweight. Boston Properties earned $1.56 in the first quarter,...

Via Benzinga

10 Biggest Price Target Changes For Monday ↗

June 14, 2021

Needham raised OrthoPediatrics Corp. (NASDAQ: KIDS) price target from $70 to $77. Vertex Pharmaceuticals shares rose 0.2% to close at $63.51 on Friday. HC Wainwright & Co....

Via Benzinga

Why Crispr's Gene-Editing Jump Wasn't Enough To Help Vertex Stock ↗

June 11, 2021

Vertex Pharmaceuticals and Crispr Therapeutics appeared Friday to be making progress on a cure for two blood diseases. But only CRSP stock popped.

Via Investor's Business Daily

Vertex, Crispr Unveil More Encouraging Data From Sickle Cell, Thalassemia Gene Therapy Trials ↗

June 11, 2021

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Crispr Therapeutics AG (NASDAQ: CRSP) have announced new data from Phase 1/2 clinical trials...

Via Benzinga

Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting

June 11, 2021

From Vertex Pharmaceuticals Incorporated

Via Business Wire

The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck ↗

June 07, 2021

Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,...

Via Benzinga

What's the Best Way to Invest in Genetics Stocks? ↗

June 07, 2021

Here are some of our experts' favorite gene editing plays for the long run.

Via The Motley Fool

How Much Will the Nkarta Deal Help CRISPR Therapeutics? ↗

June 06, 2021

Unfortunately, this isn't an endorsement by a big drug developer.

Via The Motley Fool

1 Genetics Stock to Put on Your Radar ↗

June 04, 2021

Some of our experts think this stock has tons of long-term potential.

Via The Motley Fool

Topics Cannabis

Cathie Wood's Ark Loads Up Further On Tesla And Cuts Apple Stake ↗

May 19, 2021

Cathie Wood-led Ark Investment Management on Tuesday snapped up $27.2 million worth of shares in Tesla Inc (NASDAQ: TSLA) after a two-week gap during which shares of the...

Via Benzinga

3 Healthcare Stocks That Might Soar if Biden Gets This Part of His Budget Approved ↗

May 12, 2021

A new agency could help fund the attack on this chronic disease.

Via The Motley Fool

Cathie Wood Loads Up $57M In Palantir As Stock Stages Reversal On Q1 Earnings Beat ↗

May 12, 2021

Cathie Wood-led Ark Investment Management on Tuesday snapped up 2.8 million shares, worth about $56.7 million, in Palantir Technologies Inc (NYSE: PLTR) after the data analytics...

Via Benzinga

ARKK Stocks Breakdowns and Bounces ↗

May 07, 2021

After struggling for most of the past couple of months, momentum and Tech stocks are broadly outperforming today.

Via Talk Markets

Nkarta, CRISPR Join Forces On CAR-NK Development For Cancer ↗

May 07, 2021

Nkarta Inc (NASDAQ: NKTX) has collaborated with CRISPR Therapeutics AG(NASDAQ: CRSP) to co-develop and commercialize two CAR-NK therapies, in addition to an NK+T...

Via Benzinga

The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs ↗

May 07, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6) GT Biopharma, Inc. (NASDAQ:...

Via Benzinga

< Previous 1 2

...

28 29 30 31 32 33 34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

All News about CRISPR Therapeutics AG - Common Shares

Starting at $3.75/week.

Subscribe Today